MR spectroscopy for assessment of memantine treatment in mild to moderate Alzheimer dementia

Advances in Alzheimer's Disease

Volumn 2, Issue , 2011, Pages 599-604

  Ashford, J W ^a,b   Adamson, M ^a,b   Beale, T ^b   La, D ^a   Hernandez, B ^c   Noda, A ^b   Rosen, A ^b,c   O'Hara, R ^b,c   Fairchild, J K ^b,c   Spielman, D ^b   Yesavage, J A ^b,c  

^a VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^b STANFORD UNIVERSITY   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Alzheimer disease; cognition; creatine; dementia; magnetic resonance spectroscopy; memantine; N acetylaspartate

Indexed keywords

MEMANTINE; PLACEBO;

AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; INFERIOR PARIETAL LOBULE; INTERVENTIONAL MAGNETIC RESONANCE IMAGING; MALE; N ACETYL ASPARTATE CREATININE RATIO; NERVOUS SYSTEM PARAMETERS; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OUTCOME ASSESSMENT; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL;

EID: 84865444547     PISSN: 22105727     EISSN: 22105735     Source Type: Book Series    
DOI: 10.3233/978-1-60750-793-2-599     Document Type: Article

References (16)

1. Vemuri P, Wiste HJ, Weigand SD, Shaw LM, Trojanowski JQ, Weiner MW, Knopman DS, Petersen RC, Jack CR Jr (2009) MRI and CSF biomarkers in normal, MCI, and AD subjects: diagnostic discrimination and cognitive correlations. Neurology 73, 287-293.
2. Ernst T, Chang L, Melchor R, Mehringer CM (1997) Frontotemporal dementia and early Alzheimer disease: differentiation with frontal lobe H-1 MR spectroscopy. Radiology 203, 829-836.
3. Kantarci K, Petersen RC, Boeve BF, Knopman DS, Tang-Wai DF, O'Brien PC, Weigand SD, Edland SD, Smith GE, Ivnik RJ, Ferman TJ, Tangalos EG, Jack CR Jr (2004) 1H MRspectroscopy incommon dementias. Neurology 63, 1393-1398.
4. Kantarci K (2007) 1H magnetic resonance spectroscopy in dementia. Br J Radiol 80 Spec No 2, S146-S152
5. Kantarci K, Petersen RC, Przybelski SA, Weigand SD, Shiung MM, Whitwell JL, Negash S, Ivnik RJ, Boeve BF, Knopman DS, Smith GE, Jack CR Jr (2008) Hippocampal volumes, proton magnetic resonance spectroscopy metabolites, and cerebrovascular disease in mild cognitive impairment subtypes. Arch Neurol 65, 1621-1628.
6. Modrego PJ, Fayed N, Errea JM, Rios C, Pina MA, Sarasa M (2010) Memantine versus donepezil in mild to moderate Alzheimer's disease: a randomized trial with magnetic resonance spectroscopy. Eur J Neurol 17, 405-412.
7. Murray ME, Dickson DW, Jack CR, Kantarci K (2009) Aberrant tau pathology underlies H-1MRspectroscopic alterations in Alzheimer's disease. Neurology 72, A173-A174.
8. Clerici F, Vanacore N, Elia A, Spila-Alegiani S, Pomati S, Da Cas R, Raschetti R, Mariani C (2009) Memantine in moderately-severe-to-severe Alzheimer's disease: a postmarketing surveillance study. Drugs Aging 26, 321-332.
9. Porsteinsson AP, Grossberg GT, Mintzer J, Olin JT (2008) Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. Curr Alzheimer Res 5, 83-89.
10. Rosen WG, Mohs RC, Davis KL (1984) A new rating scale for Alzheimer's disease. Am J Psychiatry 141, 1356-1364.
11. Ashford JW, Kumar V, Barringer M, Becker M, Bice J, Ryan N, Vicari S (1992) Assessing Alzheimer severity with a global clinical scale. Int Psychogeriatr 4, 55-74.
12. Braak H, Braak E (1996) Evolution of the neuropathology of Alzheimer's disease. Acta Neurol Scand Suppl 165, 3-12.
13. Jessen F, Gur O, Block W, Ende G, Frolich L, Hammen T, Wiltfang J, Kucinski T, Jahn H, Heun R, Maier W, Kolsch H, Kornhuber J, Traber F (2009) A multicenter (1)H-MRS study of the medial temporal lobe in AD and MCI. Neurology 72, 1735-1740.
14. Ashford JW, Shan M, Butler S, Rajasekar A, Schmitt FA (1995) Temporal quantification of Alzheimer's disease severity: 'time index' model. Dementia 6, 269-280.
15. Westman E, Wahlund L-O, Foy C, Poppe M, Cooper A, Murphy D, Spenger C, Lovestone S, Simmons A (in press) Combining MRI and MRS to distinguish between Alzheimer's disease and healthy controls. Journal of Alzheimer's Disease
16. Kaufer D, Gandy S (2009) APOE {epsilon}4 and bapineuzumab: Infusing pharmacogenomics into Alzheimer disease therapeutics. Neurology 73, 2052-2053.